DIVERSITY BY DESIGN
DEAD

Serial Number

97593425

Owner

SYNEOS HEALTH, LLC

Attorney

Michael A. Geller

Filing Date

Sep 15, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DIVERSITY BY DESIGN Trademark

Serial Number: 97593425

DIVERSITY BY DESIGN is a trademark filed by SYNEOS HEALTH, LLC on September 15, 2022. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

SYNEOS HEALTH, LLC (17 trademarks)

1030 SYNC STREET
MORRISVILLE, NC 27560

Entity Type: 16

Trademark Details

Filing Date

September 15, 2022

Registration Date

Not Registered

Published for Opposition

January 3, 2023

Goods & Services

Education in the field of pharmaceutical sales, namely, providing webinars, providing live workshops, providing on-line non-downloadable videos, providing on-line non-downloadable publications in the nature of articles and white papers, and providing podcasts; training services in the field of pharmaceutical sales; providing on-line non-downloadable newsletters and bulletins in the pharmaceutical, biotechnology and life sciences fields; educational services in the field of clinical trials, namely, providing on-line non-downloadable videos, webinars, live workshops, providing online non-downloadable publications in the nature of articles and white papers, and providing podcasts

Strategic business consulting, marketing and advertising, public relations communications strategy, information and data collection for business purposes, and business data analytics, namely, analyzing business data to understand and evaluate business performance, all of the aforementioned in the pharmaceutical, biotechnology and life sciences fields; sales promotion services; market analysis and research services; personnel recruitment and placement; recruitment services, namely, advertising clinical trials, recruiting patients, and placing patients for participation in clinical trials for testing of pharmaceuticals and devices; consulting in sales techniques and sales programs; sales volume tracking for others, all in the pharmaceutical, biotechnology and life sciences fields; business consulting in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, pharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; assisting pharmaceutical and biotechnology companies with applications for new drugs with governmental regulatory bodies; promoting the exchange of health information to promote patient adherence

Providing medical information to physicians, other health care professionals and for medical patients; providing health information regarding the medications and health care products of others, namely, product discontinuations, new formulations, bottle changes, and seasonal information through e-mail alerts and push notifications

Medical, scientific and data analysis research services for others, namely, conducting and analyzing clinical trials in the pharmaceutical, biotechnology and life sciences fields; pharmaceutical drug development services, namely, developing clinical trial methodologies; consulting services in the area of pharmaceutical clinical testing; extended clinical research services for others, namely, computerized data management of clinical trials, biostatistical analysis, environmental consultancy, preclinical research and development evaluation, repairing flawed clinical trials and dossiers, strategic clinical research portfolio management, and biosurveillance monitoring; providing life science and scientific research information to physicians and other health care professionals, patients, and medical, pharmaceutical and biotechnology companies; providing regulatory compliant technical writing services in the field of medical research and clinical studies; consulting services in the field of contract clinical research and contract product development

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 31, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 31, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2024 EXRA
SOU EXTENSION 3 GRANTED
Dec 10, 2024 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 9, 2024 AITU
SOU EXTENSION RECEIVED WITH TEAS PETITION
Sep 13, 2024 TPEX
NOTICE OF REVIVAL - E-MAILED
Sep 13, 2024 NREV
PETITION TO REVIVE-GRANTED
Sep 13, 2024 PETG
TEAS PETITION TO REVIVE RECEIVED
Sep 13, 2024 PROA
SOU EXTENSION 3 FILED
Aug 28, 2024 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 29, 2024 EXRA
SOU EXTENSION 2 GRANTED
Feb 28, 2024 EX2G
SOU EXTENSION 2 FILED
Feb 28, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 28, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 24, 2023 EXRA
SOU EXTENSION 1 GRANTED
Aug 22, 2023 EX1G
SOU EXTENSION 1 FILED
Aug 22, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 22, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 28, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 3, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jan 3, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 14, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 1, 2022 CNSA
ASSIGNED TO EXAMINER
Dec 1, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 30, 2022 NWOS
NEW APPLICATION ENTERED
Sep 19, 2022 NWAP